Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children

被引:0
|
作者
Carina A. Rodriguez
Sarah Koch
Maureen Goodenow
John W. Sleasman
机构
[1] University of South Florida,Department of Pediatrics, Division of Allergy, Immunology and Rheumatology
[2] College of Medicine,Division of Infectious Diseases
[3] All Children’s Hospital,Department of Pathology, Immunology, and Laboratory Medicine
[4] University of South Florida,undefined
[5] College of Medicine,undefined
[6] All Children’s Hospital,undefined
[7] University of Florida,undefined
[8] College of Medicine,undefined
来源
Immunologic Research | 2008年 / 40卷
关键词
HIV; Protease inhibitor; Thymus; Immune reconstitution; CD4 T cells;
D O I
暂无
中图分类号
学科分类号
摘要
Many HIV-infected children treated with protease inhibitors (PI) reconstitute immunity despite viral breakthrough predicting disease progression. We studied a unique cohort of PI treated children with advanced disease who demonstrated sustained CD4 T cell counts but median post therapy viral load rebounded to >4.0 log10 copies/ml. Phylogenetic relationships between pre- and post-therapy viruses reveals significant bottlenecks for quasispecies with natural polymorphisms mapping outside of protease active site providing selective advantage for emergence. Among discordant subjects post-therapy viruses fell into two phenotypes; high viral loads (median >5.0 log10 copies/ml) and attenuated post-therapy replication (median <4.0 log10 copies/ml). Both groups showed similar degrees of CD4 T cell immune reconstitution and were similar to children who optimally suppressed virus to <400 copies/ml. Both high fit and low fit discordant response groups showed high reconstitution of naïve CD4 CD45RA T cells (median 388 and 357 cells/μl, respectively). Naïve T cells increases suggest virus replicating under PI selective pressure do not impair thymic output. If therapeutic options are limited, selection of therapy which allows immune reconstitution despite suboptimal viral control may be beneficial. This novel paradigm for virus/host interactions may lead to therapeutic approaches to attenuate viral pathogenesis.
引用
收藏
页码:271 / 286
页数:15
相关论文
共 50 条
  • [1] Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children
    Rodriguez, Carina A.
    Koch, Sarah
    Goodenow, Maureen
    Sleasman, John W.
    IMMUNOLOGIC RESEARCH, 2008, 40 (03) : 271 - 286
  • [2] Viral load in HIV-infected children on high activity antiretroviral therapy
    Resino, Salvador
    Bellon, Jose M.
    Antonio Leon, Juan
    Resino, Rosa
    Munoz-Fernandez, M. Angeles
    MEDICINA CLINICA, 2007, 128 (02): : 49 - 51
  • [3] Mortality and Clinical Outcomes in HIV-Infected Children on Antiretroviral Therapy in Malawi, Lesotho, and Swaziland
    Kabue, Mark M.
    Buck, W. Chris
    Wanless, Sebastian R.
    Cox, Carrie M.
    McCollum, Eric D.
    Caviness, A. Chantal
    Ahmed, Saeed
    Kim, Maria H.
    Thahane, Lineo
    Devlin, Andrew
    Kochelani, Duncan
    Kazembe, Peter N.
    Calles, Nancy R.
    Mizwa, Michael B.
    Schutze, Gordon E.
    Kline, Mark W.
    PEDIATRICS, 2012, 130 (03) : E591 - E599
  • [4] Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children
    Buchacz, K
    Cervia, JS
    Lindsey, JC
    Hughes, MD
    Seage, GR
    Dankner, WM
    Oleske, JM
    Moye, J
    PEDIATRICS, 2001, 108 (04) : E72
  • [5] Adherence to antiretroviral treatments with a protease inhibitor in HIV-infected patients
    Salmon-Céron, D
    Deleuze, J
    Coste, J
    Guerin, C
    Ginsburg, C
    Blanche, P
    Finkielsztejn, L
    Pecqueux, L
    Chaput, S
    Gorin, I
    Sicard, D
    ANNALES DE MEDECINE INTERNE, 2000, 151 (04): : 297 - 302
  • [6] Antiretroviral Therapy in HIV-Infected Infants and Children
    Maron, Gabriela
    Gaur, Aditya H.
    Flynn, Patricia M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (04) : 360 - 363
  • [7] Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy
    Suaysod, Rapeepan
    Ngo-Giang-Huong, Nicole
    Salvadori, Nicolas
    Cressey, Tim R.
    Kanjanavanit, Suparat
    Techakunakorn, Pornchai
    Krikajornkitti, Sawitree
    Srirojana, Sakulrat
    Laomanit, Laddawan
    Chalermpantmetagul, Suwalai
    Lallemant, Marc
    Le Coeur, Sophie
    McIntosh, Kenneth
    Traisathit, Patrinee
    Jourdain, Gonzague
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (01) : 95 - 101
  • [8] Viral Suppression in a Nationwide Sample of HIV-Infected Children on Antiretroviral Therapy in Rwanda
    Nsanzimana, Sabin
    McArdle, Flannery
    Remera, Eric
    Mulindabigwi, Augustin
    Ribakare, Muhayimpundu
    Ndimubanzi, Patrick
    Kayirangwa, Eugenie
    Baribwira, Cyprien
    Riedel, David J.
    Ntaganira, Joseph
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2019, 38 (02) : 149 - 151
  • [9] Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy
    Weinberg, Adriana
    Dickover, Ruth
    Britto, Paula
    Hu, Chengcheng
    Patterson-Bartlett, Julie
    Kraimer, Joyce
    Gutzman, Howard
    Shearer, William T.
    Rathore, Mobeen
    McKinney, Ross
    AIDS, 2008, 22 (17) : 2267 - 2277
  • [10] Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children
    Abadi, J
    Sprecher, E
    Rosenberg, MG
    Dobroszycki, J
    Sansary, J
    Fennelly, G
    Wiznia, A
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (03) : 298 - 303